Baker BROS. Advisors LP Grows Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Baker BROS. Advisors LP boosted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 322.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 361,565 shares of the company's stock after acquiring an additional 276,065 shares during the period. Baker BROS. Advisors LP owned 0.63% of Structure Therapeutics worth $9,806,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $304,000. Ameriprise Financial Inc. raised its holdings in Structure Therapeutics by 29.4% in the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock worth $38,512,000 after purchasing an additional 322,601 shares in the last quarter. Boxer Capital Management LLC purchased a new position in Structure Therapeutics during the fourth quarter valued at $13,560,000. Foresite Capital Management VI LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter valued at $11,390,000. Finally, Boothbay Fund Management LLC grew its position in shares of Structure Therapeutics by 147.0% in the 4th quarter. Boothbay Fund Management LLC now owns 83,148 shares of the company's stock worth $2,255,000 after buying an additional 49,485 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Up 4.8 %

GPCR stock traded up $1.20 during midday trading on Wednesday, hitting $26.53. The company's stock had a trading volume of 536,165 shares, compared to its average volume of 924,997. The company has a market cap of $1.52 billion, a PE ratio of -35.86 and a beta of -1.69. The firm's 50-day moving average is $20.73 and its 200-day moving average is $27.20. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GPCR. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Stifel Nicolaus began coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target on the stock. Finally, Citigroup initiated coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $78.63.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.